Stuart Marcus
Founder and CSO
Stuart pioneered the development of Photodynamic Therapy Systems, with over 30 years of experience with ALA.
Mark de Souza
President and CEO
Mark has over 20 years of executive and entrepreneurial experience in the rare disease space.
Nandini Kandolha
CFO
Nandini is an experienced financial and strategic leader with over 15 years of experience in finance, accounting, audit, strategy and team building.
Joanne LaValle
Consultant, Regulatory Affairs
Joanne has over 25 years of experience in Regulatory Affairs and Pharmacovigilance focused on drug, device and combination product development and commercialization.
Brian Roden
CMC Advisor
Brian is a research chemist with 25+ years experience in the development of branded and generic pharmaceutical products.
Brian Rogers
Non-Clinical Advisor
Brian has nearly 30 years of industrial toxicology experience, including over 25 years in the biotechnology and pharmaceutical industries.
Leading our Mission
SonALAsense is led by an experienced leadership team and Scientific Advisory Board and is the first company to advance sonodynamic therapy into Phase 2 clinical trials. Our leadership has developed multiple drugs and drug-device combination therapies through FDA approval, creating the perfect team to advance Sonodynamic Therapy from bench to bedside. This team has successfully worked together for years, and, in some cases, decades.
Mitchel S. Berger, MD
Professor of Neurological Surgery and Director, Brain Tumor Center, University of California, San Francisco
Pejman Ghanouni, MD, PhD
Associate Professor, Radiology, Stanford University School of Medicine
Stuart L. Marcus, MD, PhD
Founder and Chief Scientific Officer, SonALAsense
Scott R. Plotkin, MD, PhD
Armenise Harvard Professor of Neurology, Harvard Medical School, Chief, Division of Neuro-Oncology, Massachusetts General Hospital
Graeme F. Woodworth, MD
Professor and Chair, Department of Neurosurgery, Director of the Brain Tumor Treatment & Research Center, University of Maryland School of Medicine
Margaret Dugan, MD
CMO, Dracen Pharmaceuticals, Former Senior VP & Global Program Head, Novartis Oncology
Robert Scott, MBBS
Emeritus Professor for Royal College of Ophthalmologists and Defence Medical Services
Stuart L. Marcus, MD, PhD
Founder and CSO
Mark P. de Souza, PhD
President and CEO
Vincent Sai
CEO and Partner, Modality Partnership